Re: Serologic markers of autoimmunity in women with the polycystic ovary syndromeTo the Editor:

To the Editor:

I would like to thank Dr. Hefler-Frischmuth et al. for their fine article (1). In this study, they found that women with polycystic ovary syndrome (PCOS) had significantly elevated serum levels of antihistone and anti-double-stranded DNA (anti-dsDNA) antibodies, whereas serum levels of anti-nuclear antibodies (ANAs) and antinucleosome antibodies were similar between PCOS and healthy controls. When autoimmune markers were correlated with clinical and biochemical parameters, a significant correlation between serum levels of ANAs and serum thyroid stimulating hormone (TSH) were established.

Protocol for luteal-phase clomiphene citrate in women with PCOS

To the Editor:

It was an interesting article by Badawy et al. on luteal-phase clomiphene citrate (1). There were two points on which I would like to request clarification.

Re: Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship with metabolic parameters

To the Editor:

We would like to thank Dr. Pamuk et al. for their fine article (1). In this study, they found that there were no significant differences in asymmetric dimethylarginine (ADMA) levels and intima media thickness (IMT) in polycystic ovary syndrome (PCOS) group compared with controls. In addition, there was no relationship between ADMA and IMT in the study.

Criteria for the polycystic ovary syndrome

To the Editor:

I have read with interest the extensive revision and establishment of criteria for the polycystic ovary syndrome (PCOS) by The Androgen Excess and PCOS Society (1). Certainly I agree with most of the concepts stated, but I would like to point out some with which I disagree:

Is there any difference among the most frequently used laparoscopic ovarian drilling techniques?

To the Editor:

I read with interest the article by Hendriks et al. (1) and I would like to express certain considerations. Since polycystic ovary syndrome (PCOS) ovaries in humans have different endocrinologic and morphologic properties, the normal bovine ovary model for the evaluation of the amount of damage at different energy modalities seems inadequate. The PCOS ovaries in human are mostly bigger (volume difference), contain several subcortical antral follicles (morphologic difference), are usually anovulatory (functional difference) and secrete more androgen than the non-PCOS counterparts (endocrinologic difference).

The evaluation of endothelial function with flow mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients: existence of insulin resistance alone may not represent an adequate condition for deterioration of endothelial function

To the Editor:

A recent publication entitled “The evaluation of endothelial function with flow mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary  syndrome patients: existence of insulin resistance alone may not represent an adequate condition for deterioration of endothelial function” (1) has shown that flow mediated dilatation (FMD) was not different between polycystic ovary syndrome (PCOS) and ovulatory women. The FMD in PCOS women was 24.88±9.63% and 22.35±9.40% in the control group. Comparing the values for basal brachial arterial diameter (3.54±0.37 mm and 3.81±0.66 mm; PCOS and control group, respectively) and stimulated brachial arterial diameter (4.41±0.39 mm and 4.65±0.77 mm) the observed dilation was really larger than 20% for both groups. However, the expected FMD in healthy people is 7% to 10%, while the expected FMD in patients with cardiovascular disease is 0 to 5% (2). Furthermore, the great majority of studies evaluating healthy people reported mean FMD between 3% and 15% (3).

Oligo-ovulation or anovulation and hyperandrogenemia contribute to the decreased serum adiponectin levels in normal weight women with PCOS, besides obesity and insulin resistance.

To the Editor:

We have read with great interest the excellent and well-designed study by Aroda et al. (1). We would like to comment on the potential relationship between serum adiponectin levels, obesity and insulin resistance (IR) in women with polycystic ovary syndrome (PCOS). 

Effect of sibutramine on weight reduction in women with polycystic ovary syndrome:a randomized, double-blind, placebo-controlled trial

 

 

To the Editor:

 

 

We have read with great interest the well-designed study by Lindholm et al. (1) and we would like to comment on the potential relationship between weight reduction and insulin resistance (IR) in women with polycystic ovary syndrome (PCOS) treated with sibutramine.